Survey results show a shift in pharma industry sentiment from optimism to caution as rising insecurity offsets high satisfaction and intellectual engagement.
AI and machine learning are helping pharmaceutical scientists more efficiently develop innovative and novel treatments for a range of disease areas.
Automation and supply-chain security of single-use systems are crucial for industrializing cell and gene therapy manufacturing.
Pharma industry experts indicate that strategy in 2026 is shifting to agentic AI, sustainable efficiency, and resilient supply chains to manage tariffs, regulations, and digitalization.
To combat growth and pricing pressures, companies are auditing their supply chains and API material providers.
AI and machine learning may be the ideal tools to evaluate patient data and predict ideal treatment options.
The company is adding a second production line at its Etten-Leur facility in The Netherlands to meet customer needs.
The CRDMO’s new facility will double chemistry capacity for drug discovery research and scale-up projects.
Beena Wood, Qinecsa, outlines how proactive PV, translational safety, AI foundations, and ecosystem collaboration will reshape drug safety in 2026.
Beena Wood, Qinecsa, explains how AI could revolutionize pharmacovigilance, if data, trust, skills, and organizational barriers are addressed first.
Dr. Jennifer Levin Carter, founder and CEO of Medzown, discusses what makes precision medicine different from personalized medicine and what how challenges faced in this evolving field can be overcome.
Arthur Tzianabos, CEO, Lifordi Immunotherapeutics, spoke with PharmTech about the company’s immune-directed antibody-drug conjugate (ADC) strategy, the benefits of VISTA-targeted ADCs in drug delivery, and Lifordi’s plans at the JP Morgan Healthcare Conference.
Beena Wood, Qinecsa, saw 2025 as an AI superposition in which pharmacovigilence needed better data foundations and regulation.
Saharsh Davuluri, Neuland Labs, urges API and peptide automation by 2026 to match modern biologics standards.
Elisabeth Gardiner, CSO of Tevard Biosciences, discusses how transfer RNA is impacting the development of gene therapies for diseases with unmet needs.
The company’s new AI agent automates labor-intensive processes involved in trial document management.
In Episode 31, industry veteran Deborah Dunsire goes behind the headlines to discuss the current state of innovation and evolving drug development landscape.
Mike Stenberg, LGM Pharma, explains how faster FDA approvals under CNPV shift bottlenecks to production, requiring onshoring and earlier supply chain risk.
The move brings Amgen first-in-class, small molecule-targeted protein degraders for oncology.
Laine Mello, director of marketing at Ecolab Bioprocessing, reflects on how the use of digital technologies expanded in the pharma industry in 2025 and how new complex molecules will continue to drive innovation in 2026.
Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals will receive advisory services and funding from UKRI Innovate UK and Canada’s NRC IRAP to develop next-generation genetic medicines.
Raj Puri, chief commercial officer at Argonaut Manufacturing, talks about how navigating the pressure to respond to tariffs with investments and keeping a robust and qualified staff are key moves in the new year.
Meri Beckwith, Co-CEO of Lindus Health, provides a look at how trends that developed in 2025 will impact the pharmaceutical industry in 2026.
China clears GSK’s Nucala (mepolizumab) for COPD, highlighting growing acceptance in the country for biomarker-driven therapies.
Saharsh Davuluri, Neuland Labs, discusses the move from labor to knowledge arbitrage for API manufacturers, using AI tools to empower scientists in process development.
This paper provides a technical assessment of compendial tests commonly found in the European Pharmacopoeia, the United States Pharmacopeia–National Formulary, and the Japanese Pharmacopoeia, detailing differences between the methods and acceptance criteria, and the potential impact of these differences on multi-compendial compliance.
FUJIFILM Irvine Scientific has changed its name to FUJIFILM Biosciences to better align with the company’s work in cell culture media manufacturing.
Remco Munnik, Arcana, details pharma's shift to data-first operations, AI adoption, and robust data stewardship.
Saharsh Davuluri, Neuland Labs, covers M&A blending, geopolitical shifts, and supply chain de-risking in this look back at pharma in 2025.
Manish Garg, Hikma, reflects on how AI, resilient supply chains, and smart manufacturing are reshaping pharma today and beyond.
